Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company headquartered in New York, announced on Friday that it has received confirmation from Nasdaq's Listing Qualifications Department of its regained compliance with the minimum bid price requirement specified in Listing Rule 5550(a)(2).
This notification follows the company's common stock achieving a closing bid price of at least $1.00 for ten consecutive business days, spanning from January 7 to January 22, 2025.
As of the latest report, HOTH is trading at $1.518, reflecting an increase of 3.2720% on the Nasdaq Capital Market.
